ATNM
Actinium Pharmaceuticals, Inc.
There isn't enough reported data to score ATNM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ATNM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
ATNM's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ATNM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.9x | $1.03 | -35% |
| Fair | 3.3x | $1.17 | -27% |
| Expensive | 4.2x | $1.46 | -8.1% |
| Current | 4.5x | $1.59 | — |
Historical ranges are pointers, not guarantees.
ATNM has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ATNM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ATNM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ATNM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.35 | +$1.66 |
| Q1 2026 | -$0.76 | +$0.71 |
| Q4 2025 | -$1.09 | +$0.18 |
| Q3 2025 | -$1.10 | +$0.29 |
| Q2 2025 | -$1.31 | +$0.20 |
| Q1 2025 | -$1.47 | +$0.24 |
| Q4 2024 | -$1.27 | +$0.56 |
| Q3 2024 | -$1.39 | +$0.54 |
ATNM has returned to profit: it earned $0.35 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ATNM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $45K | -81% |
| Q2 2022 | $45K | -83% |
| Q1 2022 | $940K | +51% |
ATNM has the stronger quarterly revenue trend. Revenue is up 77,678% for ATNM versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 79% | N/A |
| Q3 2025 | -6324% | N/A |
| Q3 2022 | -21776% | -18999 points |
| Q2 2022 | -17444% | -15537 points |
| Q1 2022 | -549% | +314 points |
| Q4 2021 | -34991% | N/A |
| Q3 2021 | -2776% | N/A |
| Q2 2021 | -1908% | N/A |
ATNM has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ATNM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$5.8M | +$1.7M |
| Q3 2024 | -$12M | -$820K |
| Q2 2024 | -$8M | +$5.7M |
| Q1 2024 | -$7.4M | +$7.8M |
| Q4 2023 | -$7.5M | +$304K |
| Q3 2023 | -$11.2M | -$5.4M |
| Q2 2023 | -$13.7M | -150% |
| Q1 2023 | -$15.2M | -$9.4M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ATNM at down 27%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ATNM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +169K shares |
| 1 year | +0.7% | +211K shares |
| 3 years | +20% | +5.2M shares |
| 5 years | +55% | +11.2M shares |
| Available history | +477% | +26M shares |
ATNM has 31M diluted shares, up 0.7% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ATNM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ATNM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -3.7x | Net Cash |
ATNM has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ATNM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.9 | Neutral |
| Stochastic | 82.3 | Overbought |
ATNM's weekly RSI is 64 (neutral) and its Stochastic is 82 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ATNM PE vs Healthcare Sector
| Metric | ATNM | Sector median | Relative |
|---|---|---|---|
| PE | 4.5x | 26x | 82% below |
ATNM has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ATNM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.33 | 20% above |
| 20 week MA | $1.14 | 39% above |
| 50 week MA | $1.19 | 34% above |
| 100 week MA | $1.32 | 20% above |
| 200 week MA | $3.86 | 59% below |
ATNM has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 59% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ATNM on trend strength, trading above more of its moving averages.
ATNM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.57 | $11.1 | +68% |
| 2021 | $11.1 | $6.66 | -40% |
| 2022 | $6.66 | $10.0 | +51% |
| 2023 | $10.0 | $5.08 | -49% |
| 2024 | $5.08 | $1.20 | -76% |
| 2025 | $1.20 | $1.52 | +27% |
| 2026 YTD | $1.52 | $1.59 | +4.6% |
ATNM has finished lower in three of the last six years. It's up 4.6% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ATNM on returns for 2026, with the stronger performance.